

**NATIONAL INSTITUTE FOR HEALTH AND CARE
EXCELLENCE**

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

**Dexamethasone intravitreal implant for treating diabetic macular oedema in people without a pseudophakic lens
(part review of TA349)**

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Yes, it was noted during consultation that if a person is registered as blind or partially sighted, they are considered disabled, as stated in the Equality Act 2010. Therefore, the patient population addressed in this appraisal is a protected group under this act.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the committee?

This issue will be taken into account in the committee's decision making.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No, the stakeholder matrix already included several organisations representing people with partial sight or blindness.

Approved by Associate Director (name): Jasdeep Hayre

Date: 19 October 2021